Clinical laboratories facing persistent phlebotomist shortages now have a robotic option for collecting patient blood samples.
The US Food and Drug Administration authorized Vitestro’s Aletta, the first standalone robotic device capable of drawing blood from a patient’s arm without hands-on operator intervention. The device is authorized for adults in outpatient settings and must operate under the supervision of a trained phlebotomist.
Dark Daily has followed Vitestro’s progress since 2023, when the company was developing what it described as the world’s first autonomous blood-drawing station. In March 2026, Dark Daily reported that Vitestro raised $70 million to expand clinical validation, scale manufacturing, and prepare Aletta for US commercialization. The following month, Dark Daily covered a multicenter study in which the system achieved a 94.5% first-stick success rate when it identified a suitable vein, along with a 0.3% hemolysis rate.
The Dark Report examined Aletta in March 2025, after the device received CE marking in Europe. It followed that coverage in March 2026 with an analysis of Vitestro’s $70 million financing round and the potential operational implications of autonomous phlebotomy for clinical laboratories. The FDA authorization represents Vitestro’s next major milestone, allowing the company to market Aletta in the United States.
One phlebotomist can oversee up to three Aletta devices, potentially allowing clinical laboratories to expand collection capacity without proportionally increasing staffing.
“Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists,” said Michelle Tarver, MD, PhD, director of the FDA’s Center for Devices and Radiological Health.
Automation targets labor-intensive workflows
Aletta automates nearly the entire collection process, including vein identification, needle insertion, tube changes, and bandaging. The supervising phlebotomist remains responsible for addressing problems and verifying tube order and fill levels. For laboratory leaders, the technology could offer a way to improve patient throughput, standardize collections, and deploy scarce phlebotomy staff more efficiently. The FDA granted De Novo marketing authorization to Vitestro, establishing regulatory requirements for future devices of this type. The authorization could signal a significant step toward greater automation of clinical laboratory preanalytical processes.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
